Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | NSD2 | O96028 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | ADCY10 | Q96PN6 | 4/20 | 0.37 |
| ▸ | KIT | P10721 | 3/20 | 0.34 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.34 |
| ▸ | KDR | P35968 | 3/20 | 0.34 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 2/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.33 |
| ▸ | JAK2 | O60674 | 2/20 | 0.33 |
| ▸ | JAK3 | P52333 | 2/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18339245 | 0.86 | KDM4E (0.45) | MAPTKDM4ENSD2ALDH1A1KDM4C | |
| SCHEMBL12729869 | 0.84 | KDM4E (0.58) | MAPTKDM4ENSD2ALDH1A1KDM4C | |
| SCHEMBL904782 | 0.82 | MAPT (0.61) | MAPTKDM4ENSD2ALDH1A1KDM4C | |
| SCHEMBL3436679 | 0.82 | MAPT (0.56) | MAPTKDM4ENSD2ALDH1A1KDM4C | |
| SCHEMBL24664403 | 0.79 | MAPT (0.53) | MAPTKDM4ENSD2ALDH1A1KDM4C | |
| SCHEMBL30570132 | 0.79 | MAPT (0.53) | MAPTKDM4ENSD2ALDH1A1KDM4C | |
| SCHEMBL30570094 | 0.79 | MAPT (0.53) | MAPTKDM4ENSD2ALDH1A1KDM4C | |
| SCHEMBL28265750 | 0.77 | MAPT (0.50) | MAPTKDM4ENSD2ALDH1A1KDM4C | |
| SCHEMBL30007444 | 0.76 | MAPT (0.53) | MAPTKDM4ENSD2ALDH1A1KDM4C | |
| SCHEMBL3078992 | 0.76 | IRAK4 (0.41) | MAPTKDM4ENSD2ALDH1A1MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10899752-B2 | 2,3-dihydro-4H-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-01-26 | — | — | US | disclosed |
| EP-3313836-B1 | 2,3-DIHYDRO-4H-1,3-BENZOXAZIN-4-ONE DERIVATIVES AS MODULATORS OF CHOLINERGIC MUSCARINIC M1 RECEPTOR | TAKEDA PHARMACEUTICALS CO (JP) | 2020-11-11 | — | — | EP | disclosed |
| US-10428056-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-10-01 | — | — | US | disclosed |
| US-20190248776-A1 | 2,3-DIHYDRO-4H-1,3-BENZOXAZIN-4-ONE DERIVATIVES AS MODULATORS OF CHOLINERGIC MUSCARINIC M1 RECEPTOR | TAKEDA PHARMACEUTICALS CO (JP) | 2019-08-15 | — | — | US | disclosed |
| US-10323027-B2 | 2,3-dihydro-4H-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-18 | — | — | US | disclosed |
| US-20180362516-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-12-20 | — | — | US | disclosed |
| US-10087150-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-02 | — | — | US | disclosed |
| US-20180162850-A1 | 2,3-DIHYDRO-4H-1,3-BENZOXAZIN-4-ONE DERIVATIVES AS MODULATORS OF CHOLINERGIC MUSCARINIC M1 RECEPTOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| EP-3313836-A1 | 2,3-DIHYDRO-4H-1,3-BENZOXAZIN-4-ONE DERIVATIVES AS MODULATORS OF CHOLINERGIC MUSCARINIC M1 RECEPTOR | Takeda Pharmaceutical Company Limited (JP) | 2018-05-02 | — | — | EP | disclosed |
| US-20180050996-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-02-22 | — | — | US | disclosed |
| US-9878989-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-01-30 | — | — | US | disclosed |
| WO-2016208775-A1 | 2,3-DIHYDRO-4H-1,3-BENZOXAZIN-4-ONE DERIVATIVES AS MODULATORS OF CHOLINERGIC MUSCARINIC M1 RECEPTOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-29 | — | — | WO | disclosed |
| US-20160376244-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10899752-B2 | 2,3-dihydro-4H-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor | CHRM1, CHRM4, CHRM2 | MAPT 166/4885KDM4E 742/4885NSD2 715/4885 |
| US-20180362516-A1 | HETEROCYCLIC COMPOUND | CHRM1, CHRM5, CHRM2 | MAPT 121/4885KDM4E 893/4885NSD2 605/4885 |
| US-20160376244-A1 | HETEROCYCLIC COMPOUND | CHRM1, CHRM5, CHRM2 | MAPT 121/4885KDM4E 893/4885NSD2 605/4885 |
| US-10087150-B2 | Heterocyclic compound | CHRM1, CHRM5, CHRM2 | MAPT 121/4885KDM4E 893/4885NSD2 605/4885 |
| US-20180050996-A1 | HETEROCYCLIC COMPOUND | CHRM1, CHRM5, CHRM2 | MAPT 121/4885KDM4E 893/4885NSD2 605/4885 |
| US-20190248776-A1 | 2,3-DIHYDRO-4H-1,3-BENZOXAZIN-4-ONE DERIVATIVES AS MODULATORS OF CHOLINERGIC MUSCARINIC M1 RECEPTOR | CHRM1, CHRM4, CHRM2 | MAPT 166/4885KDM4E 742/4885NSD2 715/4885 |
| US-10323027-B2 | 2,3-dihydro-4H-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor | CHRM1, CHRM4, CHRM2 | MAPT 166/4885KDM4E 742/4885NSD2 715/4885 |
| US-20180162850-A1 | 2,3-DIHYDRO-4H-1,3-BENZOXAZIN-4-ONE DERIVATIVES AS MODULATORS OF CHOLINERGIC MUSCARINIC M1 RECEPTOR | CHRM1, CHRM4, CHRM2 | MAPT 166/4885KDM4E 742/4885NSD2 715/4885 |
| US-10428056-B2 | Heterocyclic compound | CHRM1, CHRM5, CHRM2 | MAPT 121/4885KDM4E 893/4885NSD2 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.